Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

NCT05144698 is registered in ClinicalTrials.gov with Rapa Therapeutics LLC as lead sponsor.

NCT NCT05144698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05144698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors
Lead sponsor
Rapa Therapeutics LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2021
Completion date
December 31, 2026
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, head and neck cancer, malignant melanoma, small cell and non-small cell lung cancer, solid tumor, squamous cell carcinoma of larynx, squamous cell carcinoma of nasopharynx, squamous cell carcinoma of oral cavity, squamous cell carcinoma of other specified sites of skin